Analyst firms · Piper Sandler · TFX
Piper Sandler TFX price target and rating history
Teleflex Incorporated (TFX) · Health Care
Piper Sandler rates Teleflex Incorporated (TFX) Overweight with a $160 price target, as of its latest action on Jun 8, 2026. It has published 4 rating actions on TFX since January 2022, including 2 upgrades and 2 downgrades. Across 7 firms with a TFX price target in the last 12 months, the median target is $155. Piper Sandler's $160 is 3% above that.
- Current rating
- Overweight
- Price target
- $160
- Median target, all firms
- $155
- Actions on TFX
- 4
Piper Sandler price target on TFX
Every Piper Sandler rating on TFX
- Jun 8, 2026
- Feb 28, 2025
- Jul 1, 2024
- Jan 4, 2022
How other firms rate TFX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Buy | $158 | Sep 28, 2026 |
| UBS | Neutral | $145 | Jul 28, 2026 |
| BMO Capital Markets | Outperform | $159 | Jul 9, 2026 |
| Piper Sandler | Overweight | $160 | Jun 8, 2026 |
| RBC Capital Markets | Outperform | $155 | May 8, 2026 |
| Raymond James | Outperform | $128 | Mar 27, 2026 |
| Needham | Buy | $138 | Jan 27, 2026 |
Questions about Piper Sandler and TFX
- What is Piper Sandler's price target for TFX?
- Piper Sandler's latest stated price target for Teleflex Incorporated (TFX) is $160, from its action on Jun 8, 2026.
- What is Piper Sandler's rating on TFX?
- Piper Sandler rates TFX Overweight, a bullish rating, as of Jun 8, 2026.
- When did Piper Sandler last change its view on TFX?
- On Jun 8, 2026, Piper Sandler upgrades to Overweight from Neutral, price target $160.
- How does Piper Sandler's TFX target compare with other analysts?
- Across 7 firms with a TFX price target in the last 12 months, the median target is $155. Piper Sandler's $160 is 3% above that.
More TFX rating histories
All Piper Sandler ratingsTFX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.